Crypto News: Thursday’s Watchlist: We Have All Eyes On (ALBT) This Morning

Any content you receive is for information purposes only. Always conduct your own research.

*Sponsored

(ALBT) Lands at the Top of Today's Daily Edge Report Watchlist — Thursday, February 19, 2026

Don't miss the next breakout — get real-time alerts sent straight to your phone!

Take A Look At (ALBT) While It's Still Early…

February 19, 2026

Thursday's Watchlist | We Have All Eyes On (ALBT) This Morning

Dear Reader,

Sometimes the most interesting setups are the ones where multiple developments begin to line up at once.

That's exactly what we're seeing here.

This commercial-stage company, operating across diagnostics, cellular therapy, and AI-driven media, has recently delivered a series of updates that are starting to bring it onto our radar.

One of the first things that stands out is the share structure.

With a public float of roughly 3.77M shares, the supply remains relatively tight, creating the type of environment where dynamics can shift quickly as activity builds.

At the same time, the company has taken steps to strengthen its financial position.

A recent $2.6M debenture conversion eliminated a majority of outstanding debt tied to a prior financing round, reducing overhang and improving balance sheet flexibility as it advances its broader initiatives.

The company recently announced FDA registration renewal for its KetoAir™ device, alongside plans to launch across both B2B and B2C channels using its AI-powered short-form video platform, Catch-Up™, an effort designed to enhance digital engagement and marketing efficiency.

Layer in recent developments, including a major acquisition completed at the end of 2025 and a series of updates early in 2026, and this is one of the reasons Avalon GloboCare Corp. (Nasdaq: ALBT) has moved onto our radar today—Thursday, February 19, 2026.

As new developments continue to unfold, this is one we'll be watching closely this morning.

Diagnostics, Cellular Therapy & IP Development

Avalon GloboCare Corp. (Nasdaq: ALBT) is a commercial-stage company focused on precision diagnostics, cellular therapy intellectual property, and generative AI-driven software. Its product portfolio spans consumer health devices, biotechnology platforms, and AI-powered media infrastructure.

Key products and platforms include:

KetoAir™ Breathalyzer (Precision Diagnostics): A handheld, FDA-registered device (Registration #3026284320) designed to measure breath acetone levels as a biomarker for ketosis. The product uses nanosensor technology to deliver real-time, non-invasive insights into metabolic health and is intended for consumer wellness, weight management, and performance monitoring.
Catch-Up™ AI Video SaaS Platform (Generative AI Software): A fully automated software platform that creates short-form video content using AI-generated commentary, avatars, and curated video clips. The system is designed to produce and distribute content across major platforms without manual editing, and is expected to be licensed to creators, brands, and media companies.
Avalon Quantum AI (AI Infrastructure & IP): A wholly owned subsidiary focused on developing generative AI technologies, including patented systems for automated, compliance-oriented video commentary and personalized content generation. These technologies are designed to support scalable content creation while maintaining accuracy and traceability.
QTY Protein Design Platform (Cellular Therapy IP): A biotechnology platform developed in collaboration with the Massachusetts Institute of Technology (MIT), focused on engineering water-soluble protein variants, including cytokine receptors. This platform supports Avalon's efforts to build intellectual property in cellular therapy and related biomedical applications.
Additional Diagnostic Development Initiatives: Avalon is exploring expanded applications of its breathalyzer technology and related diagnostic tools, including potential new use cases in health monitoring and real-time detection systems.

(ALBT Website)

Market Landscape: Converging HealthTech, Diagnostics & Generative AI

Avalon GloboCare (Nasdaq: ALBT) is positioned across several sectors that are seeing increased attention, precision diagnostics, cellular therapy, and AI-driven digital platforms.

In diagnostics, the broader market continues shifting toward non-invasive, real-time health monitoring, with global in vitro diagnostics expected to exceed $127B by 2028. As consumers and providers focus more on early detection and continuous tracking, tools like breath-based diagnostics are gaining relevance.

At the same time, cellular therapy and biologics remain key areas of biotech innovation, with the global cell therapy market projected to reach over $48B by 2030, driven by advancements in targeted treatments and platform-based research.

On the technology side, AI in marketing and digital content is expanding rapidly. The sector is expected to grow from approximately $32.73B in 2026 to $217.33B by 2034, as companies adopt automated systems to scale content, engagement, and distribution.

Taken together, these overlapping sectors reflect a broader shift toward automation, data-driven decision-making, and scalable digital platforms, areas where multiple growth trends are evolving at the same time.

5 Key Developments That Put (Nasdaq: ALBT) On Today's Watchlist — Thursday, February 19, 2026

1. Tight Float: 3.77M shares available— limited supply profile.

2. Balance Sheet Shift: $2.6M debentures converted to equity, reducing debt from the June 2024 financing round and improving capital structure.

3. AI Patent Filing: Subsidiary Avalon Quantum AI filed a U.S. provisional patent for automated, verifiable video commentary designed for compliance-driven use cases.

4. KetoAir™ Expansion: FDA registration renewed; plans to launch across B2B and B2C channels using the Catch-Up™ AI video platform.

5. RPM Acquisition: Acquired RPM Interactive in an all-shares deal, adding generative AI video SaaS capabilities and forming Avalon Quantum AI LLC.

Take A Look At (ALBT) While It's Still Early…

Keep in mind, (ALBT) has a public float of roughly 3.77M shares, according to Yahoo Finance, meaning a relatively tight supply where shifts in attention can impact dynamics.

Layer in recent developments, including a $2.6M debt conversion that strengthened the balance sheet, expansion into AI-driven media through a newly filed patent, and the RPM Interactive acquisition, and the broader setup begins to take shape.

Add to that the planned rollout of KetoAir™ across both B2B and B2C channels using an AI-powered platform, and multiple areas of development are starting to align at once.

(ALBT) is front and center for us this morning.

Give (ALBT) a quick look right now while it's still early.

And keep an eye out for our next update, it could be hitting any moment.

Sincerely,

Joel Locke

Senior Editor

The Daily Edge Report

^{DailyEdgeReport.com}^{("DailyEdgeReport" or "DER" ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.}

_{Avalon GloboCare Corp. (ALBT:US) previously changed their symbol from Avalon GloboCare Corp. (AVCO:US)}

_{Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 02/19/2026 and ending on 02/19/2026 to publicly disseminate information about (ALBT:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Awareness Consulting Network LLC who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.}

_{Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (ALBT:US).}

_{Please see important disclosure information here:}_{https://dailyedgereport.com/disclosure/albt-oojh9/#details}